PT Kalbe Farma Tbk. (PTKFF)

USD 0.08

(0.0%)

Revenue Summary of PT Kalbe Farma Tbk.

PT Kalbe Farma Tbk.'s latest annual revenue in 2023 was 1.97 Billion USD , up 6.88% from previous year.
PT Kalbe Farma Tbk.'s latest quarterly revenue in 2024 Q3 was 522.09 Million USD , up 1627983.85% from previous quarter.
PT Kalbe Farma Tbk. reported a annual revenue of 1.85 Billion USD in annual revenue 2022, up 0.73% from previous year.
PT Kalbe Farma Tbk. reported a annual revenue of 1.83 Billion USD in annual revenue 2021, up 11.75% from previous year.
PT Kalbe Farma Tbk. reported a quarterly revenue of 522.09 Million USD for 2024 Q3, up 1627983.85% from previous quarter.
PT Kalbe Farma Tbk. reported a quarterly revenue of 526.87 Million USD for 2024 Q1, up 2.76% from previous quarter.

Annual Revenue Chart of PT Kalbe Farma Tbk. (2023 - 2015)

Historical Annual Revenue of PT Kalbe Farma Tbk. (2023 - 2015)

Year	Revenue	Revenue Growth
2023	1.97 Billion USD	6.88%
2022	1.85 Billion USD	0.73%
2021	1.83 Billion USD	11.75%
2020	1.64 Billion USD	0.9%
2019	1.63 Billion USD	11.25%
2018	1.46 Billion USD	-1.48%
2017	1.48 Billion USD	3.44%
2016	1.43 Billion USD	10.82%
2015	1.29 Billion USD	0.0%

Year	Revenue	Revenue Growth
2024 Q2	485.87 Million USD	-7.78%
2024 Q3	522.09 Million USD	1627983.85%
2024 Q1	526.87 Million USD	2.76%
2023 Q4	512.72 Million USD	6.86%
2023 FY	1.97 Billion USD	6.88%
2023 Q1	519.36 Million USD	4.69%
2023 Q2	489.75 Million USD	-5.7%
2023 Q3	479.83 Million USD	-2.03%
2022 Q2	459.54 Million USD	-5.07%
2022 FY	1.85 Billion USD	0.73%
2022 Q4	496.11 Million USD	4.45%
2022 Q3	474.96 Million USD	3.36%
2022 Q1	484.08 Million USD	-3.45%
2021 Q1	414.14 Million USD	0.0%
2021 FY	1.83 Billion USD	11.75%
2021 Q4	501.37 Million USD	6.45%
2021 Q3	470.97 Million USD	7.46%
2021 Q2	438.27 Million USD	5.83%
2020 FY	1.64 Billion USD	0.9%
2019 FY	1.63 Billion USD	11.25%
2018 FY	1.46 Billion USD	-1.48%
2017 FY	1.48 Billion USD	3.44%
2016 FY	1.43 Billion USD	10.82%
2015 FY	1.29 Billion USD	0.0%

Peer Revenue Comparison of PT Kalbe Farma Tbk.

Name	Revenue	Revenue Difference
AstraZeneca PLC	46.91 Billion USD	95.781%
Bristol-Myers Squibb Company PFD CONV 2	45 Billion USD	95.602%
CSPC Pharmaceutical Group Limited	31.45 Billion USD	93.707%
Clarus Therapeutics Holdings, Inc.	13.95 Million USD	-14080.653%
Novartis AG	46.66 Billion USD	95.758%